Portal de Periódicos da CAPES

Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

2021; Elsevier BV; Volume: 89; Linguagem: Inglês

10.1016/j.jocn.2021.05.047

1532-2653

Matías Kohler, Eduardo Köhler, Cárlos Vrech, Agustín Pappolla, Jimena Míguez, Liliana Patrucco, Jorge Correale, Mariano Marrodán, María I. Gaitán, Marcela Fiol, Laura Negrotto, María Célica Ysrraelit, Edgardo Cristiano, Adriana Carrá, Judith Steinberg, Alejandra Martínez, María Celeste Curbelo, Leila Cohen, Ricardo Alonso, Orlando Garcea, Cecilia Pita, Berenice Silva, Geraldine Luetic, Norma Deri, María Eugenia Balbuena, Verónica Tkachuk, Edgar Carnero Contentti, Pablo A. López, Juan Pablo Pettinicchi, Alejandro Caride, Marcos Burgos, Felisa Leguizamón, Eduardo Knorre, Raúl Piedrabuena, Andrés Barboza, Susana Liwacki, Pedro Nofal, Gabriel Volman, Amelia Alvez Pinheiro, Javier Hryb, Darío Tavolini, Patricio Blaya, Luciano Recchia, Carolina Mainella, Emanuel Silva, Jorge Blanche, Santiago Tizio, Maria Luisa Saladino, Fernando Cáceres, Nora Fernández Liguori, Luciana Lázaro, Gisela Zanga, Marcela Parada Marcilla, María E. Fracaro, Fátima Pagani Cassara, Guido Vázquez, Vladimiro Sinay, Gustavo Sgrilli, Pablo Divi, Miguel Jacobo, Edgardo Reich, Lorena M. Cabrera, María Laura Menichini, Mariano Coppola, Iván Martos, Juan Pablo Viglione, Gustavo José, Santiago Bestoso, Rubén Manzi, Diego Giunta, María L. Doldan, Ricardo Alonso, Juan Ignacio Rojas,

Rheumatoid Arthritis Research and Therapies

The objectives of the present study were to describe the frequency of aggressive multiple sclerosis (aMS) as well as to compare clinical and radiological characteristics in aMS and non-aMS patients included in RelevarEM (NCT 03375177). Methods The eligible study population and cohort selection included adult-onset patients (≥18 years) with definite MS. AMS were defined as those reaching confirmed EDSS ≥ 6 within 5 years from symptom onset. Confirmation was achieved when a subsequent EDSS ≥ 6 was recorded at least six months later but within 5 years of the first clinical presentation. AMS and non-aMS were compared using the χ2 test for categorical and the Mann-Whitney for continuous variables at MS onset and multivariable analysis was performed using forward stepwise logistic regression with baseline characteristics at disease onset. Results A total of 2158 patients with MS were included: 74 aMS and 2084 non-aMS. The prevalence of aMS in our cohort was 3.4% (95%CI 2.7–4.2). AMS were more likely to be male (p = 0.003), older at MS onset (p < 0.001), have primary progressive MS (PPMS) phenotype (p = 0.03), multifocal presentation (p < 0.001), and spinal cord as well as infratentorial lesions at MRI during disease onset (p = 0.004 and p = 0.002, respectively). Conclusion 3.4% of our patient population could be considered aMS. Men, patients older at symptom onset, multifocal presentation, PPMS phenotype, and spinal cord as well as brainstem lesions on MRI at clinical presentation all had higher odds of having aMS.